復星國際(00656.HK):「618」期間旗下各品牌整體銷售按年增35%
復星國際(00656.HK)公佈,「618」期間,復星旗下各消費品牌整體銷售按年增長35%,其中珠寶品類按年增76%,亞一、鬆鶴樓、金徽酒等十餘個品牌按年增長超100%,同時誕生近百個千萬及百萬級爆款單品。
集團表示,6月18日至19日,復星旗下老廟黃金、上海牌手錶、沱牌白酒、湖心亭套餐、海之光沐等一衆消費品牌在東方購物直播頻道集結,回饋更多消費者。此外,在上海堂食恢復後,豫園文化飲食集團將進行「到店餐飲」專場直播,將「星意」延續至線下門店。
復星國際亦表示,於本月13日,復星醫藥(02196.HK)生物藥平臺復宏漢霖(02696.HK)與Organon LLC公司簽署授權許可及供貨協議;根據協議,跨國藥企Organon獲得復宏漢霖自主開發的帕妥珠單抗生物類似藥 HLX11、地舒單抗生物類似藥HLX14 兩款產品,除了在中國以外,並在全球進行獨家商業化的權益,全面覆蓋美國、歐盟、日本等主流生物藥市場和衆多新興市場;復宏漢霖將從交易中獲得5.41億美元的潛在收入,其中7,300萬美元爲交易首付款。 (ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.